PO

Polydex Pharmaceuticals LtdOOTC POLXF Stock Report

Last reporting period 31 Jul, 2021

Updated —

Last price

Market cap $B

0.002

Micro

Exchange

OOTC - OTC

POLXF Stock Analysis

PO

Uncovered

Polydex Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

7/100

Low score

Market cap $B

0.002

Dividend yield

Shares outstanding

3.38 B

Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company’s products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.

View Section: Eyestock Rating